Caponnetto 2014.

Study name	Smoking cessation and reduction In schizophrenia (the SCARIS study)
Methods	3‐arm prospective 12‐m randomized controlled trial investigating efficacy and safety of EC Setting: psychiatric and smoking cessation centres, Italy Recruitment: local newspapers and radio/television advertisements
Participants	153 participants Inclusion criteria Schizophrenic in stable phase of illness Smoked at least 10 cpd over previous 5 years Aged 18 ‐ 65 In good general health Not currently attempting to quit smoke or wishing to do so in next 6m Exclusion criteria Use smokeless tobacco or NRT Pregnant or breastfeeding Current or recent (1 yr) history of drug or alcohol abuse Other significant co‐morbidities
Interventions	12‐wk supply of: EC, high nicotine (24 mg) EC, no nicotine (0 mg, with tobacco aroma) PAIPO nicotine‐free inhalator
Outcomes	Follow‐up visits at 4, 8, 12, 24 and 52 weeks Outcome measures: Smoking cessation Smoking reduction (≥ 50% from baseline) Adverse events Quality of life Neurocognitive functioning Participant perceptions and satisfactions with products
Starting date	September 2014
Contact information	Pasquale Caponnetto, p.caponnetto@unict.it
Notes